Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.47 |
| ▸ | PRCP | P42785 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076023 | 0.89 | KDM1A (0.58) | KDM1ARECQLL3MBTL1TRPM8PRCP | |
| SCHEMBL22728969 | 0.80 | PRCP (0.69) | KDM1ARECQLL3MBTL1PRCPGAA | |
| SCHEMBL3057995 | 0.80 | PRCP (0.69) | KDM1ARECQLL3MBTL1PRCPGAA | |
| SCHEMBL3052805 | 0.80 | PRCP (0.69) | KDM1ARECQLL3MBTL1PRCPGAA | |
| SCHEMBL3066459 | 0.76 | KDM1A (0.67) | KDM1AL3MBTL1PRCPHTR2AHTR2C | |
| SCHEMBL4063542 | 0.74 | KDM1A (0.50) | KDM1ARECQLL3MBTL1TRPM8PRCP | |
| SCHEMBL3062224 | 0.73 | KDM1A (0.67) | KDM1AL3MBTL1PRCP | |
| SCHEMBL4064540 | 0.72 | KDM1A (0.51) | KDM1ARECQLL3MBTL1TRPM8PRCP | |
| SCHEMBL3956419 | 0.72 | KDM1A (0.51) | KDM1ARECQLL3MBTL1TRPM8PRCP | |
| SCHEMBL3962688 | 0.72 | L3MBTL1 (0.53) | KDM1ARECQLL3MBTL1TRPM8PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009038812-A1 | CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009038812-A1 | CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | KDM1A 3375/4885RECQL 3197/4885L3MBTL1 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.